Reviewing OPKO Health Inc. (OPK)’s and Prothena Corporation plc (NASDAQ:PRTA)’s results – MS Wkly

Both OPKO Health Inc. (NASDAQ:OPK) and Prothena Corporation plc (NASDAQ:PRTA) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of OPKO Health Inc. and Prothena Corporation plc.

Profitability

Table 2 shows OPKO Health Inc. and Prothena Corporation plcs return on equity, net margins and return on assets.

Volatility and Risk

OPKO Health Inc. is 113.00% more volatile than Standard & Poors 500 due to its 2.13 beta. Prothena Corporation plc on the other hand, has 2.24 beta which makes it 124.00% more volatile compared to Standard & Poors 500.

Liquidity

OPKO Health Inc. has a Current Ratio of 1.1 and a Quick Ratio of 1. Competitively, Prothena Corporation plcs Current Ratio is 27.9 and has 27.9 Quick Ratio. Prothena Corporation plcs better ability to pay short and long-term obligations than OPKO Health Inc.

Insider and Institutional Ownership

Roughly 26.4% of OPKO Health Inc. shares are held by institutional investors while 92.7% of Prothena Corporation plc are owned by institutional investors. 5.5% are OPKO Health Inc.s share held by insiders. Comparatively, insiders own roughly 90.1% of Prothena Corporation plcs shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year OPKO Health Inc.s stock price has bigger decline than Prothena Corporation plc.

Summary

OPKO Health Inc. beats Prothena Corporation plc on 6 of the 10 factors.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinsons disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dn Laoghaire, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the original post:
Reviewing OPKO Health Inc. (OPK)'s and Prothena Corporation plc (NASDAQ:PRTA)'s results - MS Wkly